Mergers & acquisitions
Nektar is reportedly exploring various strategic options, including a possible sale, partnerships or licensing agreements.
NCPC GeneTech, the biotech division of North China Pharma, in-licensed China rights for a biosimilar to a second-gen renal anemia treatment from South Korea’s CJ Healthcare.
Amgen reported its fourth-quarter financials yesterday, but in anticipation of this year’s hot merger-and-acquisition market, a lot of focus has been on the company’s considerable available cash.
Only a week after launch, Partner Therapeutics acquired the global rights to Leukine from Sanofi.
The company expects to only pay a tax rate of 9 percent this year, which will free up a lot of cash.
Seattle Genetics is paying $10 per share in cash for Cascadian.
With 2018 expected to be a big year for mergers and acquisitions in the biopharma industry, analysts and investors are considering who the top targets might be.
A look at three small biotechs that big drugmakers are drooling over.
Only a week after Sanofi ponied up $11.6B to buy Waltham, Massachusetts-based Bioverativ, the French drugmaker is buying Ghent, Belgium-based Ablynx for $4.8B.
We are still only in January and Celgene and Sanofi have already made a combined $20B in M&A deals.
PRESS RELEASES